Global Vaccines Market to Reach $94 Billion by 2030 at 11.9% CAGR | GlaxoSmithKline, Pfizer, Moderna Lead Competitive Race

The global vaccines market, valued at $48 billion in 2024 (excluding COVID-19 vaccine sales), will more than double to $94 billion by 2030, advancing at a compound annual growth rate of 11.9% over the forecast period. Mounting infectious disease burdens, accelerating investment in next-generation vaccine platforms, and sustained government immunization commitments across developed and emerging economies are collectively fueling this expansion.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/preventive-vaccines/request-sample.html

Market Overview: A Sector Responding to a Global Health Imperative
Vaccines are biological preparations that train the immune system to recognize and neutralize specific pathogens, providing active acquired immunity before exposure to disease. From eradicating smallpox to containing the measles resurgence, vaccination has historically delivered the highest return on investment in public health. Today, the urgency around that mission is intensifying again.

The World Health Organization documented 64 new infectious diseases affecting human populations in January 2023 alone. The European Centre for Disease Prevention and Control reported nearly 4.5 million dengue cases globally by November 2023, with approximately 4,000 confirmed deaths. Avian influenza A and Mpox outbreaks drew fresh WHO attention in mid-2024. Simultaneously, roughly 2 million people suffering from rotavirus require hospitalization each year. These numbers are not abstractions for pharmaceutical executives; they represent direct demand signals for a sector capable of scaling production quickly.

Investment is already following that signal. French President Emmanuel Macron joined African leaders in committing to a $1.1 billion project to accelerate vaccine manufacturing capacity across the continent. In June 2024, Biovac and Sanofi formalized a partnership to produce inactivated polio vaccines in Africa, targeting supply to more than 40 countries. The U.S. Biomedical Advanced Research and Development Authority announced over $500 million in funding for Project NextGen, backing Phase 2b clinical trials of intranasal and oral COVID-19 vaccine candidates. These are material, named programs, not projections, and they underpin the market's growth trajectory through 2030.

Key Growth Drivers
Rising infectious disease incidence. The frequency and geographic spread of outbreaks, from Mpox in Central Africa to dengue in Southeast Asia and the Americas, continues to widen the addressable population for preventive vaccines. The WHO reported that measles vaccination coverage among children improved from 81% in 2021 to 83% in 2022, reflecting both growing demand and improved program reach. Each new outbreak event reinforces the case for expanded immunization schedules.

Government and multilateral immunization programs. National governments are embedding vaccination deeper into primary healthcare infrastructure. In February 2023, the Government of India signed a three-year partnership with Gavi, the Vaccine Alliance, under which Gavi committed $250 million to reach unvaccinated children and introduce HPV and typhoid conjugate vaccines into India's routine immunization schedule. Programs of this scale create multi-year procurement certainty for manufacturers.

Next-generation vaccine technology. mRNA platforms, recombinant vaccines, and DNA vaccine formats are shortening development timelines and improving efficacy profiles. In June 2024, Moderna confirmed that its next-generation COVID-19 vaccine candidate met Phase III trial endpoints, demonstrating non-inferior efficacy and improved shelf life. GlaxoSmithKline and CureVac restructured their collaboration in July 2024, with GSK acquiring full development and commercialization rights to mRNA vaccines for COVID-19 and influenza in a deal potentially worth €1.45 billion plus royalties.

Expanding adult immunization market. Historically concentrated in pediatrics, vaccine demand is broadening toward adults as endemic disease risks grow and health systems focus on reducing hospitalization costs among working-age and elderly populations. GlaxoSmithKline's RSV vaccine Arexvy generated GBP 1.2 billion in sales in its 2023 launch year in the United States, a clear commercial signal that adult immunization carries substantial revenue potential.

Strategic capital deployment by startups and investors. Early-stage funding rounds are targeting differentiated delivery platforms. In January 2026, Centivax closed a $45 million oversubscribed Series A led by Future Ventures for its universal influenza vaccine program, advancing toward a Phase I trial start within eight months. Startups such as Vaxart and iosBio are developing oral tablet-based vaccines, seeking to eliminate cold-chain requirements that currently complicate distribution in lower-income regions.

Market Segmentation: Who Buys, What Gets Injected, and How
Live attenuated vaccines currently hold the largest share at 28% of the global vaccines market by vaccine API type, driven by the broad clinical record of live attenuated formulations across influenza, MMR, varicella, and rotavirus indications. However, the "others" category, which encompasses newer modalities including DNA vaccines, mRNA vaccines, and peptide-based formats, holds the second-largest share and will grow at the fastest rate across vaccine API segments at 16.8% CAGR through 2030.

By patient population, the pediatric segment leads with 56% of market share in 2024, supported by national childhood immunization schedules that drive consistent, policy-backed procurement. The adult segment, however, will outpace it over the forecast horizon at a CAGR of 12.1%, reflecting the expanding commercial case for adult vaccines across respiratory, oncology-adjacent (HPV), and emerging infectious disease categories. By route of administration, intramuscular delivery commands 52% market share in 2024, favored for its reliable pharmacokinetic profile and tolerability. The intravenous segment will grow fastest at 14.6% CAGR. By specific vaccine type, pneumococcal conjugate vaccines hold 25.8% of market share; Pfizer's Prevnar series and Merck's newly FDA-approved 21-valent CAPVAXIVE (approved June 2024) are the dominant products in that segment. MMR vaccines will register the highest growth rate among specific vaccine types at 12.3% CAGR through 2030.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/preventive-vaccines/request-quote.html

Regional Insights: North America Leads, Asia-Pacific Accelerates
North America accounts for 44% of global vaccines market revenue in 2024, a position built on several structural advantages: a mature healthcare reimbursement infrastructure, high per-capita immunization rates, strong regulatory frameworks that attract first-market launches, and sustained private-sector R&D investment in the United States. The region benefits disproportionately from the adult immunization expansion, given the commercial success of products like Arexvy and Merck's CAPVAXIVE across the U.S. market.

Asia-Pacific is the fastest-growing regional segment at a projected CAGR of 14.7% through 2030. India's partnership with Gavi and the resulting $250 million commitment to close immunization gaps represents one of the largest single-country immunization investment signals of recent years. China, Japan, and South Korea are each advancing domestic vaccine manufacturing and pipeline programs. The region's combination of large unvaccinated or under-vaccinated populations, rising healthcare spending, and expanding manufacturing infrastructure makes it the most consequential growth market for vaccine companies pursuing volume-driven revenue strategies over the next decade.

Competitive Landscape: Incumbent Scale Meets Platform Innovation
The key companies profiled in the vaccines market include Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva.

GlaxoSmithKline currently holds 21% of the overall vaccines market share, the largest of any single player, supported by its breadth of marketed products. Its shingles vaccine SHINGRIX generated GBP 3.4 billion in revenue in 2023. Pfizer and Merck dominate the pneumococcal conjugate segment. Moderna is rapidly building a multi-product vaccine portfolio on its mRNA platform, expanding well beyond COVID-19. The competitive dynamic is not a straightforward consolidation story; rather, incumbents are defending large-product franchises while simultaneously racing to secure mRNA and next-generation platform positions, often through licensing and partnership structures. Startup activity on oral delivery and thermostable formulations adds a disruptive layer that incumbent manufacturers are monitoring closely through acquisition pipelines and in-licensing deals. In January 2026, Pfizer secured a $530 million agreement with Novavax for non-exclusive rights to Matrix-M adjuvant technology, illustrating how even the largest players are acquiring platform access rather than building all capabilities internally.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/preventive-vaccines/318.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.